P=N/A, N=22, Active, not recruiting, Adverum Biotechnologies, Inc. | Enrolling by invitation --> Active, not recruiting

P3, N=35, Completed, Alvotech Swiss AG | Active, not recruiting --> Completed

We analyzed pretreatment cfDNA from a cohort nested in CALGB 90601 (Alliance), a first-line trial of gemcitabine/cisplatin with bevacizumab or placebo in mUC. Higher amounts of tumor DNA in blood and mutations in specific cancer genes were linked to worse survival. The results may help in the design of new studies to improve survival for patients with advanced bladder cancer.This trial is registered on ClinicalTrials.gov as NCT00942331.

Pembrolizumab monotherapy significantly improved survival over bevacizumab-based chemotherapy in metastatic MSI-H/dMMR CRC, with a manageable safety profile. These results reinforce PD-1 inhibitors as first-line therapy for this population, while highlighting tumor mutation burden (TMB) and tumor burden as critical biomarkers for personalized strategies.

P2, N=120, Recruiting, Genentech, Inc. | Trial primary completion date: May 2026 --> Sep 2026

TIL counts, including those of CD3+ and CD8+ TILs, in the peritumoral area were significantly higher after ATZ/BEV than after LEN therapy.

In China, cadonilimab plus chemotherapy is not considered cost-effective compared to standard chemotherapy as a first-line treatment for the general p/r/m CC population. However, it represents a cost-effective option for patients ineligible for bevacizumab therapy.

Second, we performed a retrospective analysis of lung cancer patients who received bevacizumab or anlotinib to assess the incidence of VEGF/VEGFRI-associated TEEs and bleeding...In the cohort study, bevacizumab, aflibercept, and ramucirumab showed the strongest associations with VTE, ATE, and bleeding, respectively...All VEGF/VEGFRIs were associated with increased ATE and bleeding risk. VEGF/VEGFR-targeted biologics also significantly raise the risk of VTE.

These findings could be crucial for the implementation of personalised treatment strategies for unresectable HCC. However, identifying optimal therapeutic options for patients with unresectable HCC and high serum FGF21 levels remains an urgent and critical clinical issue.

P1, N=31, Completed, Innovent Biologics (Suzhou) Co. Ltd. | Unknown status --> Completed

P=N/A, N=3000, Not yet recruiting, Bayer

P3, N=2432, Active, not recruiting, National Cancer Institute (NCI) | N=3610 --> 2432 | Trial completion date: Aug 2025 --> Apr 2026

P2, N=221, Recruiting, Fudan University

P=N/A, N=478, Active, not recruiting, Radboud University Medical Center | Recruiting --> Active, not recruiting | Trial completion date: Jul 2025 --> Jul 2027 | Trial primary completion date: Jul 2023 --> Jan 2025

P2, N=40, Recruiting, Tata Memorial Centre | Trial completion date: Dec 2024 --> Dec 2029 | Trial primary completion date: Dec 2024 --> Dec 2027

P2, N=454, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2025 --> Feb 2026

P3, N=4994, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2025 --> Feb 2026

In this real-world study of patients receiving niraparib-bevacizumab first-line maintenance, the majority of whom had HRp/HR status unknown, the median time to next treatment was consistent with observed progression-free survival in patients with similar HR status in the OVARIO study.

Post-chemoradiation glioblastomas with a diffusion MRI phenotype that is known to predict a favorable response to anti-VEGF (ADCL ≥1240 µm2/s) have distinct biological features, with different perfusion and metabolic characteristics, and T2 relaxation times.

The addition of afuresertib to paclitaxel did not significantly improve PFS/OS in patients with PROC. However, exploratory biomarker findings suggest potential efficacy in phospho-AKT positive patients, warranting further investigation. The safety/tolerability profile of A + P was consistent with prior AKT-inhibitor studies.

P1/2, N=20, Completed, University Hospital, Caen | Recruiting --> Completed | N=30 --> 20

P1/2, N=54, Recruiting, Northwell Health | Trial completion date: Oct 2026 --> Oct 2027 | Trial primary completion date: Oct 2025 --> Oct 2026

BETINA study demonstrated promising efficacy and favorable tolerance in treating patients with mTNBC with bevacizumab with tislelizumab and nab-paclitaxel.

P1/2, N=54, Suspended, Northwell Health | Trial completion date: Dec 2026 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2026

P1, N=30, Suspended, Northwell Health | Trial completion date: Jan 2025 --> Jan 2027 | Trial primary completion date: Jan 2025 --> Jan 2026

P=N/A, N=550000, Not yet recruiting, Regeneron Pharmaceuticals | Initiation date: Jan 2025 --> Apr 2025 | Trial primary completion date: Feb 2025 --> May 2025

P3, N=434, Not yet recruiting, Rophibio, Inc. | Initiation date: Jan 2025 --> Jul 2025

P3, N=49, Recruiting, Sixth Affiliated Hospital, Sun Yat-sen University | Not yet recruiting --> Recruiting

VEGF inhibitors are associated with a very high risk of cardiomyopathy according to the ESC guidelines(2022). These side effects in conversion therapy for cancer should be carefully considered, even though they are rare.

P3, N=574, Completed, AGO Research GmbH | Active, not recruiting --> Completed | Trial primary completion date: Dec 2024 --> Mar 2025

Circulating miR-485-3p is a more sensitive biomarker than VEGFA for the early prediction of therapeutic response in atezo/bev therapy for HCC.

P1, N=27, Not yet recruiting, University of Alabama at Birmingham | Phase classification: P1/2 --> P1

P2, N=64, Active, not recruiting, Biotheus Inc. | Phase classification: P2/3 --> P2 | N=374 --> 64 | Trial primary completion date: Mar 2025 --> Sep 2024

P2, N=150, Not yet recruiting, Innovent Biologics Technology Limited (Shanghai R&D Center)

P3, N=49, Not yet recruiting, Sixth Affiliated Hospital, Sun Yat-sen University

P=N/A, N=30, Not yet recruiting, The First Hospital of Jilin University; Department of Radiotherapy, The First Hospital of Jilin University

P=N/A, N=40, Not yet recruiting, Shanghai Ninth People's Hospital， Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital， Shanghai JiaoTong University

P2, N=22, Not yet recruiting, The 10th Hospital of Southern Medical University (Dongguan People's Hospital); The 10th Hospital of Southern Medical University (Dongguan People's Hos

P2, N=46, Not yet recruiting, The Affiliated Panyu Central Hospital, Guangzhou Medical University; The Affiliated Panyu Central Hospital, Guangzhou Medical University

P=N/A, N=30, Completed, Cancer Hospital, Chinese Academy of Medical Sciences; San Huan Cancer Hospital, Chaoyang District

P2, N=30, Not yet recruiting, Sichuan Cancer Hospital; Sichuan Cancer Hospital

P=N/A, N=30, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University